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Abstract
Background: V-ATPases constitute a ubiquitous family of heteromultimeric, proton translocating
proteins. According to their localization in a multitude of eukaryotic membranes, they energize
many different transport processes. Since their malfunction is correlated with various diseases in
humans, the elucidation of the properties of this enzyme for the development of selective inhibitors
and drugs is one of the challenges in V-ATPase research.
Results: Archazolid A and B, two recently discovered cytotoxic macrolactones produced by the
myxobacterium Archangium gephyra, and apicularen A and B, two novel benzolactone enamides
produced by different species of the myxobacterium Chondromyces, exerted a similar inhibitory
efficacy on a wide range of mammalian cell lines as the well established plecomacrolidic type V-
ATPase inhibitors concanamycin and bafilomycin. Like the plecomacrolides both new macrolides
also prevented the lysosomal acidification in cells and inhibited the V-ATPase purified from the
midgut of the tobacco hornworm, Manduca sexta, with IC50 values of 20–60 nM. However, they did
not influence the activity of mitochondrial F-ATPase or that of the Na+/K+-ATPase. To define the
binding sites of these new inhibitors we used a semi-synthetic radioactively labelled derivative of
concanamycin which exclusively binds to the membrane Vo subunit c. Whereas archazolid A
prevented, like the plecomacrolides concanamycin A, bafilomycin A1 and B1, labelling of subunit c
by the radioactive I-concanolide A, the benzolactone enamide apicularen A did not compete with
the plecomacrolide derivative.
Conclusion:  The myxobacterial antibiotics archazolid and apicularen are highly efficient and
specific novel inhibitors of V-ATPases. While archazolid at least partly shares a common binding
site with the plecomacrolides bafilomycin and concanamycin, apicularen adheres to an independent
binding site.
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Background
Vacuolar-type ATPases (V-ATPases) are ubiquitous proton
pumps in the endomembrane system of all eukaryotic
cells and in plasma membranes of many animal cells
where they energize transport processes across the mem-
brane or regulate the pH of corresponding compartments
[1]. They are heteromultimeric enzymes consisting of a
membrane bound, proton translocating Vo complex and a
catalytic V1  complex which is oriented towards the
cytosol. In recent years it became more and more evident
that malfunction of the V-ATPase is correlated with a mul-
titude of diseases such as osteopetrosis, male infertility or
renal acidosis [2-4]. Therefore the V-ATPase turned out to
be a subject for biomedical research and even was consid-
ered as a potential target for cancer drug therapy [5]. In
order to understand the development of these diseases
and to design efficient drugs for their therapy it is neces-
sary to gain a most comprehensive knowledge of the
mode of action of the enzyme as well as of known V-
ATPase inhibitors on the one hand, and, on the other
hand, to search for novel potent and specific inhibitors
with different inhibition characteristics.
The best examined and established specific V-ATPase
inhibitors are the plecomacrolides bafilomycin [6] and
concanamycin [7], which both take effect in nanomolar
concentrations by binding to the Vo subunit c [8-10].
Recently various new inhibitors of V-ATPases such as the
benzolactone enamides [11] or chondropsines [12] have
been described (reviewed in [13]) but so far in no case the
binding site has been determined. Only for the benzolac-
tone enamide salicylihalamide it was shown that its bind-
ing site is different to that of plecomacrolides [10] and
may reside somewhere between the Vo and the V1 complex
[14]. In the present report we introduce two types of anti-
biotics produced by myxobacteria, apicularens, new ben-
zolactone enamides [15,16] and archazolids, a novel class
of macrolactones [17] which both represent highly potent
and specific V-ATPase inhibitors, however, with different
modes of action and different binding sites.
Results and Discussion
Archazolid and apicularen influence the viability of 
mammalian cell-lines
The novel antibiotics archazolids and apicularens (Fig. 1)
were checked for their impact on the cell growth of a vari-
ety of mammalian cell lines from different tissues (Tab.
1). For nearly all of them IC50 values were in the nanomo-
lar range, comparable with the IC50 values for concanamy-
cin A and bafilomycin A1. Apicularen B was the only
exception, with an average IC50 value two orders of mag-
nitude higher. Growth inhibition of the multidrug-resist-
ant cell line KB-V1 was also measured in the presence of
verapamil. As this compound inactivates the Pgp efflux
pump, a comparison of the IC50 values obtained in the
presence and in the absence of verapamil revealed to
which extent the compounds were pumped out of the
cells by the MDR1 Pgp. The data in Tab 1. show, that
unlike the archazolids, the apicularens are poor substrates
of Pgp. To visualize the impact of the antibiotics, PtK2
(potoroo kidney) cells were incubated with the inhibitors
and stained for intact acidic lysosomes (Fig. 2). Evidently,
in the presence of apicularen A and archazolid A as well as
in the presence of concanamycin A and of bafilomycin A1
(not shown) the red staining, indicating acidic lysosomes,
disappeared compared to cells which had not been treated
by drugs. The same observation was made with KB-3-1
cells (data not shown). These results provided the first
indication that the novel antibiotics, like concanamycin
or bafilomycin, are interfering with the V-ATPase which is
the obligatory acidifier of lysosomes. Unlike the cell lines
listed in Tab. 1, the growth of PtK2 cells was not com-
pletely stopped. The same holds true for A-498 cells
(human kidney carcinoma). Both cell lines grow epithe-
lial-like. There was obviously a differential reaction of cell
lines to V-ATPase inhibitors. For A-431 cells (human epi-
dermoid carcinoma) a dependence on the expression of
the EGF receptor was shown [18].
Table 1: Growth inhibition of different mammalian cell lines by antibiotics
Cell line Origin ArcA ArcB ApiA ApiB BafA1 ConA
IC50 (nM)
L-929 murine connective tissue 0.81a 1.1a 4.5 620 3.2a 0.23a
3Y1 rat, embryogenic fibroblast cell line 0.95 1.1 3.2 310 5.6 1.4
KB-V1b human cervix carcinoma 48.0 35.0 23.0 1600 7.2 28.0
KB-V1b (in presence of 11 µM verapamil) 2.3 1.5 7.9 540 4.0 2.7
A-594 human lung carcinoma 0.54 0.69 0.23c 310c 0.4 0.17
M1 mouse, embryogenic fibroblast cell line 0.27 0.35 1.4 190 2.6 0.56
a [17]; b mdr cell line; c [15]
DSMZ: L-929, KB-V1, A-594
3Y1: [33]
M1: [30]BMC Biochemistry 2005, 6:13 http://www.biomedcentral.com/1471-2091/6/13
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Structure of the antibiotics Figure 1
Structure of the antibiotics. A, I-concanolide A (9-O-[p-(trifluoroethyldiazirinyl)-benzoyl]-21,23-dideoxy-23-[125I]iodo-con-
canolide A). B, archazolid A and B. C, apicularen A and B.
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Inhibition of lysosomal acidification by the novel inhibitors Figure 2
Inhibition of lysosomal acidification by the novel inhibitors. Potoroo kidney cells (PtK2) were treated with V-ATPase 
inhibitors for 4 hours and stained for lysosomes (red) with the acidotropic reagent LysoTracker, for mitochondria with 
MitoTracker (A, green) or for nuclei with Hoechst 33258 (B, blue). The control cells show many red vesicles indicating acidic 
lysosomes whereas in cells treated with the inhibitors only few red spots can be observed.
Control
Apicularen A (110 nM) Archazolid A (6.8 nM)
Concanamycin A (5.6 nM)
Control Concanamycin A (5.6 nM)
Apicularen A (110 nM) Archazolid A (6.8 nM)
A
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The V-ATPase is highly sensitive to archazolid and 
apicularen
To verify our assumption, we tested the inhibitory efficacy
of archazolid A and B as well as of apicularen A and B on
the purified V-ATPase holoenzyme from the midgut of the
tobacco hornworm. As shown in Fig. 3, both archazolids
inhibited the purified enzyme half-maximally at a con-
centration of ca. 20 nM, equivalent to an IC50 value of ca.
0.8 nmol per mg of protein. Apicularen A and B inhibited
the purified enzyme half-maximally at concentrations of
ca. 20 nM and 60 nM, respectively, equivalent to IC50 val-
ues of ca. 0.8 nmol and 2.4 nmol per mg of protein. These
inhibitory values were in the same concentration range as
those measured for the plecomacrolides concanamycin A,
bafilomycin A1 and B1, and of the benzolactone enamide
salicylihalamide which all exhibited a half-maximal inhi-
bition at ca. 10 nM and an IC50 of ca. 0.5 nmol per mg of
protein [10]. Thus the novel compounds are highly effi-
cient V-ATPase inhibitors.
These findings confirmed our assumption that growth
inhibition and the morphological changes induced by
archazolid and by apicularen were due to their inhibitory
effect on the V-ATPase. Apicularen B was slightly lower
active compared to the other drugs, but the difference is
much less than expected from the cell culture assays. This
Inhibition of the V1/Vo holoenzyme activity by the antibiotics Figure 3
Inhibition of the V1/Vo holoenzyme activity by the antibiotics. Values represent the means ± S.D. of three independent 
enzyme preparations. Archazolid A (open circles), archazolid B (solid circles), apicularen A (open triangles) and apicularen B 
(solid triangles). The specific enzyme activity of the controls without inhibitors was 1.5 ± 0.2 µmol*mg-1 *min-1.
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difference may result from a lower membrane permeabil-
ity of apicularen B due to its additional N-acetyl-β-D-glu-
cosamine residue.
While the macrolactones (archazolid A and B) and the
benzolactone enamides (apicularen A and B, salicylihala-
mide) were shown to be potent growth inhibitors of cul-
tured mammalian cells, they all failed to inhibit bacterial
growth, while only archazolid showed weak activity
against fungi; in addition, the benzolactone enamide sal-
icylihalamide effectively inhibited mammalian V-ATPases
but not at all V-ATPases from fungi such as Saccharomyces
cerevisiae  or  Neurospora crassa [11,15,17]. Since the
tobacco hornworm V-ATPase is very sensitive to all these
antibiotics and available in milligram amounts, it appears
to be an appropriate model for further investigations on
the mechanism of inhibition by archazolid and the ben-
zolactone enamides.
Archazolid and apicularen do not appear to inhibit F-and 
P-ATPases
Having shown the high sensitivity of the V-ATPase to the
two novel antibiotics, we also wanted to estimate their
inhibitory effect on F-and P-type ATPases. In various cell
cultures growth was inhibited at nanomolar concentra-
tions (see above). Therefore we asked, whether a concen-
tration of 1 µM which is fairly enough to knock out V-
ATPase activity and which is clearly higher than the IC50
values in the growth experiments, would also affect F-
ATPases such as the mitochondrial ATP-synthase or P-
ATPases such as the plasma membrane Na+/K+-ATPase.
Thus, we prepared mitochondria rich crude membranes
from mouse heart and submitochondrial particles from
beef heart as well as highly purified, Na+/K+-ATPase con-
taining plasma membranes from pig kidney, and tested
the inhibitory potential of archazolid and of apicularen.
To detect F-ATPase activity we used its specific inhibitors,
azide or oligomycin [19], and ouabain or vanadate were
used as specific inhibitors of the Na+/K+-ATPase [20,21].
Whereas the ATPase activity in the mouse and beef heart
preparations was reduced to values around 25% by the
specific F-ATPase inhibitors azide or oligomycin, the new
antibiotics archazolid and apicularen as well as the estab-
lished specific V-ATPase inhibitors concanamycin and
bafilomycin reduced the activity only slightly to approxi-
mately 80% (Fig. 4). An increase of the inhibitor concen-
tration to 10 µM for archazolid and apicularen had no
substantial effect. As shown in Tab. 2, Na+/K+-ATPase
activity was completely inhibited by 1 mM vanadate and
by 1 mM ouabain, whereas it was only slightly affected by
apicularen A and by archazolid A. A slight inhibition of
comparable size was also observed for the established
inhibitor of V-ATPases, concanamycin A, corroborating
the well known fact that plecomacrolidic antibiotics start
to inhibit P-ATPases at concentrations in the micromolar
range [6,7]. Taken together our results with F-and P-
ATPases strongly suggest that archazolid and apicularen
are specific V-ATPase inhibitors.
Archazolid and apicularen bind to different parts of the V-
ATPase
To investigate the mode of V-ATPase inhibition in more
detail, we used the semi synthetic derivative of concan-
amycin, 9-O-[p-(trifluoroethyldiazirinyl)benzoyl]-21,23-
dideoxy-23-[125I]iodo-concanolide A (I-concanolide A,
Fig. 1) which already had been used successfully to iden-
tify the binding site of plecomacrolides in V-ATPases
unambiguously [10]. In our previous study we had shown
that the Vo subunit c is the only subunit of the V-ATPase
which is labelled by I-concanolide A and that this label-
ling could be prevented by pre-incubation with the ple-
comacrolides concanamycin A, bafilomycin A1 and B1. In
a comparable UV-radiation experiment labelling of subu-
nit c by I-concanolide A was completely abolished by pre-
incubation with archazolid A (Fig. 5), thus indicating that
plecomacrolides and archazolid A share, at least partially,
the same binding site in subunit c.
Unlike archazolid, the benzolactone enamide apicularen
A did not appear to interfere with labelling of subunit c by
the concanolide A derivative because the signal obtained
was almost as strong as in the control (Fig. 4). Therefore
we suggest that apicularen binds to a site which is largely
different from that for the plecomacrolides. This result is
in agreement with our former observation that the
benzolactone enamide salicylihalamide does not bind to
subunit c and supports our conclusion that the sites and
mechanisms of inhibition for benzolactone enamides are
different from those for plecomacrolides [10].
Conclusion
The novel antibiotics archazolid and apicularen are highly
efficient and specific novel inhibitors of V-ATPases.
Table 2: Inhibition of Na+/K+-ATPase from pig kidney by 
antibiotics
specific activity µmol*mg-1 *min-1
experiment 1 experiment 2
control without inhibitors 19.0 15.9
vanadate 0.1 mM 2.0 n. d.
vanadate 1 mM 0 0
ouabain 0.1 mM 5.2 n. d.
ouabain 1 mM 0 0
concanamycin A 1 µM 16.7 12.7
apicularen A 1 µM 17.3 13.2
archazolid A 1 µM 17.1 12.2BMC Biochemistry 2005, 6:13 http://www.biomedcentral.com/1471-2091/6/13
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Despite the different structures of archazolid and the ple-
comacrolides they probably have a similar mode of inhi-
bition and their binding sites in the V-ATPase have at least
a considerable overlap. In contrast, apicularen which
demonstrates the same inhibition efficacy does not
interfere with I-concanolide A, thus suggesting a mode of
inhibition different from that of the plecomacrolides.
Methods
Enzyme preparations
The V-ATPase holoenzyme was purified as published else-
where [10]. Preparation of highly purified membranes
containing Na+/K+-ATPase from pig kidney followed the
protocol of Jørgensen [22] with the three main steps of
differential centrifugation, incubation with SDS in the
presence of ATP and sucrose density gradient centrifuga-
tion in a fixed angle rotor, and led to a specific enzyme
activity which was in the same range as that reported by
the authors. The resulting sample was stored frozen at -
20°C. To prepare crude membrane extracts, the hearts of
three mice were washed three times with an ice-cold
buffer of pH 8.1 consisting of 0.25 M sucrose, 5 mM Tris-
HCl, 5 mM EDTA, and 10 mM Pefabloc SC (Biomol),
homogenized in 5 ml of this buffer and centrifuged at 4°C
for 25 min at 233,000 × gmax in a fixed angle rotor. The
resulting pellet was resuspended in 5 ml of a buffer of pH
Inhibition of F-ATPase activity in crude membranes from mouse heart and submitochondrial particles from beef heart Figure 4
Inhibition of F-ATPase activity in crude membranes from mouse heart and submitochondrial particles from 
beef heart. Values represent the means ± S. D. of three (mouse heart) or four (beef heart) independent experiments., respec-
tively. The specific ATPase activity without inhibitor was 0.16 ± 0.05 µmol*mg-1 *min-1 in mouse heart crude membranes (blue 
columns) and 6.1 ± 0.35 µmol*mg-1 *min-1 in submitochondrial particles of beef heart (red columns). Solitary columns indicate 
that the conditions were only tested either for mouse or for beef heart.
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7.5, consisting of 5 mM Tris-MOPS (3-morpholinopro-
panesulfonic acid), 10 mM NaCl, 10 mM Pefabloc SC, 9.6
mM 2-mercaptoethanol, 0.53 mM EGTA and 0.1 % Triton
X-100. After an aliquot for protein determination had
been taken, 10% bovine serum albumin (final concentra-
tion) was added to the suspension which was then stored
on ice until the activity assays were run. Beef heart mito-
chondria were isolated by differential centrifugation, fol-
lowing the protocol of Smith by using a blender to
homogenize the heart mince [23]. The initial homogeni-
zation buffer consisted of 250 mM saccharose, 10 mM
KH2PO4, 10 mM Tris, 2 mM EGTA, 2 mM MgCl2, pH 7.4,
and further isolation procedures were carried out in the
same medium without EGTA [24]. Submitochondrial par-
ticles were obtained by ultrasonic treatment of the
mitochondria.
Antibiotics
Labelled I-concanolide A was synthesized as described
elsewhere [25]. Archazolid A and B, apicularen A and B,
concanamycin A and bafilomycin A1 and B1 were isolated
according to published procedures [15-17,26]. To avoid
freeze-thaw cycles which have significant influence on the
stability of the substances, aliquots of stock solutions in
dimethyl sulfoxide were stored at -70°C and thawed only
once immediately before use. The actual concentrations of
the stock solutions were determined
spectrophotometrically.
ATPase assays
Standard V-ATPase assays with a final volume of 160 µl
and a pH of 8.1 consisted of 3–4 µg of protein, 50 mM
Tris-MOPS, 3 mM 2-mercaptoethanol, 1 mM MgCl2, 20
mM KCl, 0.003% C12E10, 20 mM NaCl, and 3 mM Tris-
HCl. After 5 min of pre-incubation at 30°C with or with-
out inhibitors, 1 mM Tris-ATP was added and after
incubation for 2 min the reaction was stopped by placing
the tube in liquid nitrogen. Assays using Na+/K+-ATPase
were performed in 160 µl at pH 7.5 and contained 0.5 µg
of protein, 50 mM Tris-MOPS, 5 mM imidazole, 0.2 mM
EDTA, 4 mM MgCl2, 20 mM KCl and 100 mM NaCl. After
5 min of pre-incubation at 37°C with or without inhibi-
tors, 3 mM Tris-ATP was added and after 1 min of incuba-
tion the reaction was stopped by placing the tube in liquid
nitrogen. Assays using crude membranes from mouse
heart had a volume of 160 µl and a pH of 7.5, and con-
sisted of 10 µg of membrane protein, 50 mM Tris-MOPS,
3 mM 2-mercaptoethanol, 1 mM MgCl2, 20 mM KCl, 100
mM NaCl, 0.02% Triton X-100 and 0.3 mg/ml BSA. After
5 min of pre-incubation at 30°C with or without inhibi-
tors, 1 mM Tris-ATP was added and after an incubation
time of 10 min the reaction was stopped by placing the
tubes in liquid nitrogen. ATPase assays with submito-
chondrial particles from beef heart were performed in a
final volume of 1 ml and a pH of 8.0. The samples con-
tained 9–12 µg protein, 50 mM Tris, 50 mM KCl and 2.5
mM MgCl2. After 5 min of preincubation with or without
inhibitors, 5 mM ATP was added, and after an additional
incubation time of 15 min the reaction was stopped by
the addition of 0.4 ml of 20 % TCA.
Inorganic phosphate produced in the assays of V-ATPase,
Na+/K+-ATPase and mouse heart F-ATPase was measured
according the protocol of Wieczorek et al. [27], while the
determination of inorganic phosphate produced in the
assays of beef heart F-ATPase followed the method of
Fiske and Subarrow [28] using ascorbic acid as reducing
agent.
Protection of the binding site for I-concanolide A by ple- comacrolidic antibiotics Figure 5
Protection of the binding site for I-concanolide A by 
plecomacrolidic antibiotics. Tricine-SDS-PAGE gels. Lane 
1, stained with Coomassie Blue; lane 2–8, autoradiography of 
the gel after exposition to a phosphoscreen. Samples of 20 
µg V-ATPase were preincubated for 60 min on ice with 100 
µM or 10 µM bafilomycin B1 (lanes 3 and 4), 100 µM or 10 
µM apicularen A (lanes 5 and 6) and 100 µM or 10 µM arc-
hazolid (lanes 7 and 8), respectively. I-concanolide A was 
then added to give a final concentration of 10 µM. The mix-
ture was incubated for another 60 min on ice and then 
treated with UV light. Control with pre-incubation, but with-
out effectors (lane 2).
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Labelling
Twenty micrograms of the samples were pre-incubated
with the inhibitors for 1 h on ice. The labelled I-concano-
lide A was then added to give a final concentration of 10
µM. Controls were run without effectors. Mixtures with
volumes of 40 µl were incubated for an additional 1 h on
ice and then treated for 3 min with UV light (366 nm) on
ice. After UV irradiation, 10 µl of 5-fold sample buffer [10]
was added, the mixture was heated for 45 s at 95°C,
cooled on ice, and subjected to Tricine-SDS-PAGE (16.5%
T, 3% C separating gel and 10%T, 3% C spacer gel [29]),
followed by Coomassie staining. The gels were sealed in
plastic wrap before they were exposed to a phosphoscreen
for up to 72 h and analyzed with the aid of a phosphoim-
ager (Molecular Dynamics).
Cell culture and growth inhibition assay
Cell lines were obtained from the German Collection of
Microorganisms and Cell Cultures (DSMZ). Cell lines 3Y1
and M1 (embryonal fibroblasts from 129/Ola × C57BL/6
mice, [30]) were a generous gift from Dr. S. Miyamoto,
Fukoka, Japan, and Dr. P. F. Mühlradt, Braunschweig,
Germany. All cell lines were cultivated under conditions
recommended by the supplier. Growth inhibition was
measured in microtiterplates. Aliquots of 120 µl of the
suspended cells (50,000/ml) were given to 60 µl of a serial
dilution of the inhibitor. After 5 days, growth was deter-
mined using the MTT assay [31].
Cell staining
PtK2 (ATCC CCL-56) or KB-3-1 cells were grown on glass
coverslips (13 mm diameter) in four-well-plates. Expo-
nentially growing cells were incubated with the inhibitors
for 4 hours and stained for lysosomes with 50 nM Lys-
oTracker Red DND-99 and for mitochondria with 75 nM
MitoTracker Green FM (both from Molecular Probes) at
37°C for 30 min. The nuclei were stained using Hoechst
33258 (5 µg/ml). The coverslips were mounted upside
down in PBS, fixed with nail polish, and observed under
the fluorescent microscope.
Other procedures
Fifth instar larvae of M. sexta (Lepidoptera, Sphingidae),
weighing 6–8 g, were reared under long day conditions
(16 h of light) at 27°C using a synthetic diet modified
according to Bell et al [32].
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